无码影视中文高清_亚洲天堂光棍影院_欧美激情欧美激情在线五月_国产精品日韩免费观看_一级黄色毛片成人影院_六月综合激情_亚洲av无码区国产乱码粉嫩_无遮挡免费视频_97操射操射人人色_可以免费观看的黄色完整版网站视频

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
绝色狂妃 仙魅 小说,古风小说,怎样写网络小说
首頁(yè) > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Mouse Anti-PPAR delta  antibody (bsm-33263M)  
~~~促銷代碼KT202411~~~
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@bioss.com.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
說(shuō)明書(shū): 50ul  100ul  200ul
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價(jià)
產(chǎn)品編號(hào) bsm-33263M
英文名稱 Mouse Anti-PPAR delta  antibody
中文名稱 D型-過(guò)氧化酶活化增生受體單克隆抗體
別    名 FAAR; MGC3931; NR1C2; NUC1; NUCI; NUCII; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferative activated receptor delta; Peroxisome proliferator-activated receptor beta (PPAR-beta); Peroxisome proliferator-activated receptor beta; Peroxisome proliferator-activated receptor delta; PPAR beta; PPAR-beta; PPAR-delta; PPAR-? PPARB; PPARD; PPARD_HUMAN.  
Specific References  (1)     |     bsm-33263M has been referenced in 1 publications.
[IF=4.248] Lv Xiaoting. et al. αCGRP deficiency aggravates pulmonary fibrosis by activating the PPARγ signaling pathway. GENES IMMUN. 2023 May;:1-10  IHC,IF ;  Rat,Mouse,Human.  
研究領(lǐng)域 心血管  免疫學(xué)  
抗體來(lái)源 Mouse
克隆類型 Monoclonal
克 隆 號(hào) 4H10
交叉反應(yīng) (predicted: Human,Mouse,Rat)
產(chǎn)品應(yīng)用 WB=1:500-2000,ICC/IF=1:100-500
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 48kDa
細(xì)胞定位 細(xì)胞核 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 Recombinant human PPAR delta Protein 
亞    型 IgG
純化方法 affinity purified by Protein G
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Heterodimer with the retinoid X receptor. Subcellular located at nuclear Tissue specificity: Heart, adrenal and intestine. Belongs to the nuclear hormone receptor family. NR1 subfamily. It Contains 1 nuclear receptor DNA-binding domain.

Function:
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand.

Subcellular Location:
Nucleus.

Tissue Specificity:
Ubiquitous with maximal levels in placenta and skeletal muscle.

Similarity:
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

SWISS:
Q03181

Gene ID:
5467

Database links:

Entrez Gene: 5467 Human

Entrez Gene: 19015 Mouse

Entrez Gene: 25682 Rat

Omim: 600409 Human

SwissProt: Q03181 Human

SwissProt: P35396 Mouse

Unigene: 696032 Human

Unigene: 328914 Mouse

Unigene: 96181 Rat



類固醇受體(Steroid Receptors)
研究人員指出該分子的功能,極可能就是阻斷心血管免疫發(fā)炎反應(yīng)的訊號(hào)傳遞過(guò)程。PPAR-delta基因是控制肌肉發(fā)展的重要基因,在增加老鼠耐力的同時(shí)還能幫助它燃燒掉脂肪,研究人員發(fā)現(xiàn),對(duì)于與新陳代謝有關(guān)的各項(xiàng)疾病,從心臟病到肥胖癥都有啟發(fā)性的意義,他可以阻止脂肪沉淀在動(dòng)脈壁上,進(jìn)而防止動(dòng)脈硬化癥的發(fā)生,該蛋白參與脂肪代謝、肥胖、糖尿病、動(dòng)脈硬化和癌癥的發(fā)病。
在動(dòng)脈硬化現(xiàn)象發(fā)生的早期,免疫細(xì)胞會(huì)促使血管慢性的發(fā)炎,因而造成血管不斷地吸收和輸送脂肪,進(jìn)而導(dǎo)致脂肪的堆積與血管硬化,而PPAR-delta就像警衛(wèi)分子一樣,時(shí)時(shí)降低發(fā)炎反應(yīng)和抑制動(dòng)脈硬化斑的形成,因此該分子應(yīng)該是相關(guān)藥物研發(fā),相當(dāng)值得切入的目標(biāo)。
研究人員認(rèn)為,這個(gè)發(fā)現(xiàn)將給藥廠研發(fā)治療心血管疾病的新藥提供新的線索。
版權(quán)所有 2004-2026 xiaowangchong.cn 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)